This report covers the 68 geographical markets and provides an Excel-based forecast model for the Parkinson’s Disease market through 2033.
GlobalData estimates that drug sales for PD in 2023 were approximately $3.4 billion across the 7MM. With an estimated $2.1 billion in drug sales in 2023, the US dominated the PD market, contributing 63.3% of the sales in the 7MM. The high market share is primarily due to the large PD prevalent population coupled with the cost of drugs, which is significantly higher in the US compared to other countries in the 7MM. The 5EU market contributed $674.3 million in sales in 2023, accounting for 20.0% of the global market. Japan contributed sales of $560.4 million in 2023, representing 16.6% of the total global market. GlobalData anticipates that the PD market will grow to be worth approximately $7.9 billion by 2033, at a compound annual growth rate (CAGR) of 8.9%. The US is expected to maintain its position as the market leader in 2033.
Across the 68 markets, sales in the Parkinson’s Disease market were $5.7billion in 2023, growing to $12.4 billion in 2033. The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 59.5% and 63.5% of 68-market sales in 2023 and 2033, respectively.
Scope of Report
Overview of Parkinson’s Disease, including epidemiology, symptoms, diagnosis, and disease management.
Annualized Parkinson’s Disease therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Parkinson’s therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Parkinson’s treatment. The most promising candidates in late-stage development are profiled.
Analysis of the current and future market competition in the global Parkinson’s Disease therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Key Highlights
Current treatments for both early and advanced stage patients focus on controlling the level of dopamine in the brain.
GlobalData’s anticipate that 17 late stage pipeline drugs will launch over the forecast period. These will begin address longstanding unmet needs and are expected to be the main driver of growth in the PD market across the 7MM.
Roche/Prothena’s, a monoclonal antibody, has a novel MOA in the PD market and, if approved, will be revolutionary with potential neuroprotective properties.
The unmet need for therapies for treating late stage complications, such as wearing off, dyskinesia, and psychosis will remain unmet in the 5EU and Japan.
Opportunities are expected for pharmaceutical companies to develop drugs which have novel MOAs; which have potential disease modifying properties.
Reasons to buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the 7MM Parkinson’s Disease therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM Parkinson’s Disease therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Key Stakeholders
Table of Contents
Tables
Table 1: Parkinson’s Disease: Key Metrics in the 7MM
Table 2: Modified HY Scale of PD Symptoms
Table 3: Movement Disorder Society-Sponsored Revision of the Unified PD Rating Scale (MDS-UPDRS), 2008
Table 4: Risk Factors and Comorbidities of PD
Table 5: Treatment Guidelines for PD
Table 6: Parkinson’s Disease Market – Global Drivers and Barriers, 2019-2029
Table 7: Key Events Impacting Sales for Parkinson’s Disease in the US, 2019-2029
Table 8: Parkinson’s Disease Market – Drivers and Barriers in the US, 2019-2029
Table 9: Key Events Impacting Sales for Parkinson’s Disease in the 5EU, 2019-2029
Table 10: Parkinson’s Disease Market – Drivers and Barriers in the 5EU, 2019-2029
Table 11: Key Events Impacting Sales for PD in Japan, 2019-2029
Table 12: PD Market – Drivers and Barriers in Japan, 2019-2029
Table 13: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
Graphs
Figure 1: Global Sales Forecast by Country for Parkinson’s Disease in 2019 and 2029
Figure 2: Analysis of the Company Portfolio Gap in Parkinson’s Disease During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of Parkinson’s Disease During the Forecast Period
Figure 4: 7MM, Diagnosed Prevalence (%) of PD, Both Sexes, Ages ≥18 Years, 2019
Figure 5: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of PD
Figure 6: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of PD Segmented by HY Clinical Staging
Figure 7: 7MM, Diagnosed Prevalent Cases of PD, N, Both Sexes, Ages ≥18 Years, 2019
Figure 8: 7MM, Diagnosed Prevalent Cases of PD, N, by Sex, Ages ≥18 Years, 2019
Figure 9: 7MM, Diagnosed Prevalent Cases of PD by Age, N, Both Sexes, 2019
Figure 10: 7MM, Diagnosed Prevalent Cases of PD by HY Clinical Staging, N, Both Sexes, Ages ≥18 Years, 2019
Figure 11: 7MM, Diagnosed Prevalent Cases of PD by Type, N, Both Sexes, Ages ≥18 Years, 2019
Figure 12: Treatment Algorithm for Parkinson’s Patients
Figure 13: Unmet Needs and Opportunities in PD
Figure 14: Pharmacokinetics of Levodopa
Figure 15: Overview of the Development Pipeline in Parkinson’s Disease
Figure 16: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for PD in the 7MM During the Forecast Period
Figure 17: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Parkinson’s Disease During the Forecast Period
Figure 18: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Sinemet
Figure 19: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Requip
Figure 20: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Nuplazid
Figure 21: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Azilect
Figure 22: Analysis of the Company Portfolio Gap in Parkinson’s Disease During the Forecast Period (2019-2029)
Figure 23: Global (7MM) Sales Forecast by Country for Parkinson’s Disease in 2019 and 2029
Figure 24: Sales Forecast by Class for Parkinson’s Disease in the US in 2019 and 2029
Figure 25: Sales Forecast by Class for Parkinson’s Disease in the 5EU in 2019 and 2029
Figure 26: Sales Forecast by Class for PD in Japan in 2019 and 2029








